Acquisitions and Divestiture (Details) (USD $)	3 Months Ended		6 Months Ended			6 Months Ended			6 Months Ended				3 Months Ended	6 Months Ended
	Jun. 30, 2011	Mar. 31, 2011	Jun. 30, 2011	Jun. 30, 2010	Dec. 31, 2010	Jun. 30, 2011 Abraxis BioScience Inc [Member]	Oct. 15, 2010 Abraxis BioScience Inc [Member]	Jan. 15, 2010 Gloucester Pharmaceuticals Inc [Member]	Jun. 30, 2011 Equity Received [Member]	Jun. 30, 2011 Royalty Stream [Member]	Jul. 31, 2011 European Union PTCL [Member]	Jul. 31, 2011 Shareholder Of Gloucester [Member]	Mar. 31, 2011 Abraxis Acquisition [Member]	Jun. 30, 2011 Abraxis Acquisition [Member]	Jun. 30, 2011 Contribution Agreements [Member]
Additional Acquisitions (Textuals) [Abstract]
Cash payments for the acquisition								$ 338,900,000
Royalty Commencement Year			2014
Sales price in cash															110,000,000
Non-cash consideration received in divestiture			10% equity ownership in an entity that was formed with certain of the non-core assets with revenue producing potential, or Nant Holdings, and a future royalty stream based on net sales of certain products of Nant Holdings. The royalties, which commence in 2014 at the earliest and are not to exceed an annual amount of $128.0 million, will be calculated based on a range between 10% and 12.5% of net sales of certain future products. Dr. Patrick Soon-Shiong holds an option to purchase the 10% equity ownership in Nant Holdings from the Company for a price of $15.0 million at any time prior to April 2013".
Potential cash payments in cash								300,000,000			120,000,000	180,000,000
Business Acquisition Contingent Consideration Potential Cash Payment Range To Right Holder						Ranges from no payment if no regulatory milestones are met, to a maximum of $650 million in milestone payments plus payments based on annual net sales levels achieved if all milestones are met at the earliest target dates and sales exceed threshold amounts.
Total consideration transferred							3,205,000,000
Milestone payment 1							250,000,000
Milestone payment 2, achieved in time if achieved no later than April 1, 2013							400,000,000
Milestone payment 2, achieved in time if achieved after April 1, 2013							300,000,000
Net sales payments condition one							2.5% of the net sales of Abraxane ® and the Abraxis pipeline products that exceed $1 billion but are less than or equal to $2 billion for such period
Net sales payments condition two							Condition one plus An additional amount equal to 5% of the net sales of Abraxane ® and the Abraxis pipeline products that exceed $2 billion but are less than or equal to $3 billion for such period
Net sales payments condition three							Condition two plus An additional amount equal to 10% of the net sales of Abraxane ® and the Abraxis pipeline products that exceed $3 billion for such period
Net sales payments termination condition							If net sales for the net sales measuring period ending on December 31, 2025 are equal to or greater than $1 billion, then the net sales payment termination date i.e. 31 Dec 2025 will be extended until the last day of the net sales measuring period subsequent to December 31, 2025 during which net sales of Abraxane ® and the Abraxis pipeline products are less than $1 billion or, if earlier, December 31, 2030
Change in value of contingent consideration	17,700,000	105,600,000	111,169,000	(10,754,000)										123,300,000
Impairment of acquired in-process research and development			118,000,000										118,000,000
Non-cash consideration amount in divestiture									14,000,000	170,000,000
IPR&D acquired from Abraxis														1,290,000,000
Revised current Fair value of assets acquired														1,172,000,000
Acquisitions and Divestiture (Textuals) [Abstract]
Loss on sale of the non-core assets			2,900,000
Contingent Consideration	265,100,000		265,100,000
Other current liabilities	180,000,000		180,000,000
Other non-current liabilities	85,100,000		85,100,000
Business acquisition contingent value rights related liabilities	$ 88,700,000		$ 88,700,000		$ 212,000,000